BioCentury
ARTICLE | Clinical News

Bardoxolone methyl: Ph II/III started

March 2, 2017 10:59 PM UTC

Reata began a U.S. Phase II/III trial to evaluate bardoxolone in 210 patients with the rare form of chronic kidney disease (CKD). The open-label Phase II portion will enroll up to 30 patients. Adult patients with albumin to creatinine ratio (ACR) >300 mg/g will receive 5 mg once-daily oral bardoxolone at week 1, 10 mg at week 2, 20 mg at week 4 and 30 mg at week 6. Patients with ACR ≤300mg/g will receive a maximum of 20 mg. Patients ages <18 years will receive 5 mg every other day for week 1 and once-daily 5 mg starting week 2. ...